In the adjuvant setting, the ongoing ADAURA trial (ADjuvant-AURA; NCT02511106) is a double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of osimertinib vs. placebo in patients with EGFR-mutated stage IB–IIIA NSCLC following complete tumor resection. Here, EGFR is linked to neoplasm.